4.7 Review

Cyclodextrins: Only Pharmaceutical Excipients or Full-Fledged Drug Candidates?

Journal

PHARMACEUTICS
Volume 14, Issue 12, Pages -

Publisher

MDPI
DOI: 10.3390/pharmaceutics14122559

Keywords

cyclodextrin; inclusion complex; non-covalent interaction; cholesterol extraction; direct protein action; ion channels; Niemann-Pick type C disease; atherosclerosis; neurodegenerative diseases

Funding

  1. National Research, Development and Innovation Office, Hungary [FK143400, ANN133421, K138075, K143071, K132906]
  2. National Research, Development and Innovation Fund [UNKP-22-4-II-DE-69]

Ask authors/readers for more resources

Cyclodextrins are a versatile family of cyclic oligosaccharides that can form non-covalent host-guest inclusion complexes in pharmaceutical formulations. They have extensive applications in the pharmaceutical field due to their ability to enhance the solubility, stability, and bioavailability of drug molecules. Despite being considered inert carriers, cyclodextrins can interact not only with small molecules but also with lipids and proteins, influencing protein function indirectly through alterations in biophysical properties and lateral heterogeneity of bilayers. These interactions have great potential in therapy but have not been fully explored yet.
Cyclodextrins, representing a versatile family of cyclic oligosaccharides, have extensive pharmaceutical applications due to their unique truncated cone-shaped structure with a hydrophilic outer surface and a hydrophobic cavity, which enables them to form non-covalent host-guest inclusion complexes in pharmaceutical formulations to enhance the solubility, stability and bioavailability of numerous drug molecules. As a result, cyclodextrins are mostly considered as inert carriers during their medical application, while their ability to interact not only with small molecules but also with lipids and proteins is largely neglected. By forming inclusion complexes with cholesterol, cyclodextrins deplete cholesterol from cellular membranes and thereby influence protein function indirectly through alterations in biophysical properties and lateral heterogeneity of bilayers. In this review, we summarize the general chemical principles of direct cyclodextrin-protein interactions and highlight, through relevant examples, how these interactions can modify protein functions in vivo, which, despite their huge potential, have been completely unexploited in therapy so far. Finally, we give a brief overview of disorders such as Niemann-Pick type C disease, atherosclerosis, Alzheimer's and Parkinson's disease, in which cyclodextrins already have or could have the potential to be active therapeutic agents due to their cholesterol-complexing or direct protein-targeting properties.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available